Abstract
In this cross-sectional study, we investigated the seroprevalence of SARS-CoV-2 antibodies in workers of radio and television (TV) in Sergipe state, Northeast Brazil. The study was conducted from December 1 to December 20, 2020, considered the beginning of the second wave of COVID-19 in the state. Our findings showed a high seroprevalence of SARS-CoV-2 antibodies in radio and TV workers, especially among those in the production and operation teams. Prevention and control protocols against COVID-19 should be revised and implemented by media companies. Broadcast media workers should be prioritized in COVID-19 vaccine strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
To all frontline workers who are facing the COVID-19 pandemic. This study is part of the EpiSERGIPE project which is supported by grant SES/FAPESE/UFS 001/2020. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of the Federal University of Sergipe (protocol number 33095120.4.0000.5546).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author.
